| Closed |
SWOG-9413 |
Phase II Treatment with Etoposide (E), Leucovorin (L), 5-Fluorouracil (F) and Interferon Alpha 2b (I), (ELFI) + G-CSF for Locally Advanced or Recurrent Pancreatic Adenocarcinoma |
5/1/1995 |
3/15/1996 |
100% |
|
Published
|
| Closed |
SWOG-8729 |
Phase II Trial of Low Dose PALA and High Dose 5-FU as a Short Term Infusion in the Treatment of Adeno-carcinoma of the Pancreas |
3/1/1988 |
1/1/1990 |
77% |
|
Published
|
| Closed |
SWOG-7841 |
Phase II-III Comparison of FAM vs DHAD in the Treatment of Advanced Gastric Adenocarcinoma |
2/16/1979 |
8/25/1982 |
|
|
|
| Closed |
SWOG-8905 |
Phase II/III Study of Fluorouracil (5-FU) and its Modulation in Advanced Colorectal Cancer |
8/1/1989 |
1/1/1993 |
100% |
|
Published
|
| Closed |
S1815 |
Phase III Randomized for advanced biliary tract cancers |
12/3/2018 |
2/15/2021 |
100% |
|
|
| Closed |
SWOG-8734 |
Phase ll Trial of Low Dose PALA and High Dose 5-FU as a Short Term Infusion in the Treatment of Adeno-carcinoma of the Stomach |
3/1/1988 |
1/1/1990 |
86% |
|
Published
|
| Closed |
SWOG-9051 |
Pilot Evaluation of Combined Hepatic Chemoembolization and Systemic Chemotherapy with 5-FU and Folinic Acid for Metastatic Adenocarcinoma of the Colon and Rectum, Phase II |
4/15/1992 |
4/1/1995 |
100% |
|
Published
|
| Closed |
SWOG-9009 |
Pilot Study for Analysis of Lymphocyte Subsets and Natural Killer Activity after Treatment with Levamisole |
12/15/1990 |
8/7/1992 |
95% |
|
Published
|
| Closed |
SWOG-8572 |
Pilot Study of Continuous Low-Dose 5-Fluorouracil Infusion and Radiation Therapy as Adjuvant Treatment for Duke's-C Colon and Rectal Cancer |
5/9/1986 |
6/15/1991 |
64% |
|
Published
|
| Closed |
S1115 |
Rando Phase II of AZD-6244 add MK-2206 vs mFOLFOX in Pts with Met Pancreatic Cancer After Chemo |
8/15/2012 |
5/15/2014 |
100% |
|
Published
|
| Closed |
S1310 |
Rando PII GSK1120212 vs 5-FU/Leucovorin or Capecitabine for Refractory Advanced Biliary |
2/15/2014 |
5/15/2015 |
60% |
|
|
| Open |
S1922 |
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma |
12/16/2019 |
|
83% |
|
|
| Open |
S2104 |
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors |
10/14/2021 |
|
54% |
|
|
| Closed |
S1406 |
Rano Ph II of Irino+Cetuximab +/- Vemurafenib in BRAF mutant mCRC |
11/13/2014 |
4/1/2016 |
100% |
|
|
| Closed |
SWOG-9304 (INT-0144) |
RECTAL |
3/1/1994 |
8/1/2000 |
98% |
|
Published
|
| Closed |
S0304 |
RECTAL |
8/1/2004 |
2/1/2006 |
0% |
|
|
| Closed |
S1513 |
RPh II of 2nd Line FOLFIRI w/ or w/o Veliparib (ABT888) in met panc cancer |
9/1/2016 |
|
86% |
|
|
| Closed |
S1613 |
RPh II Pertuzumab+Trastuzumab vs CETIRI mCRC w/HER2 amp |
10/9/2017 |
12/31/2021 |
42% |
|
|
| Closed |
SWOG-8518 |
Study of Combined Modality Treatment For Inoperable Squamous Cell Carcinoma of the Esophagus (Stage III By Moss Classification) |
10/15/1986 |
6/1/1988 |
|
|
|
| Closed |
SWOG-8614 |
Temporarily Closed: 4/15/90, Chemotherapy of Gastric Cancer with VM-26 |
10/15/1988 |
9/15/1990 |
66% |
|
Published
|
